Reimbursement of Novo Nordisk’s weight-loss drug Wegovy for the 900,000 people in Denmark who are considered obese would cost the Danish state as much as $4 billion each year, the country’s health ministry said on Monday. Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. It was also found to have a clear cardiovascular benefit, which could boost Novo Nordisk’s hopes of positioning it as more than a lifestyle drug. The company said on Friday it aims to convince European governments to pay for Wegovy for the most overweight, or those with co-morbidities. Reimbursing Wegovy for the roughly 900,000 Danes with a body mass index (BMI) of 30 or above would cost
Hence then, the article about wegovy reimbursement would cost denmark up to 4 billion each year ministry reports was published today ( ) and is available onTOP world News today ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Wegovy reimbursement would cost Denmark up to $4 billion each year, ministry reports )